Lung cancer trial uses genetic 'Leftovers' to guide smarter immunotherapy
NCT ID NCT07120698
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is for people with stage II-IIIB non-small cell lung cancer whose tumors did not fully disappear after initial chemotherapy plus immunotherapy. Researchers will use a blood test to look for tiny bits of cancer DNA (called MRD) to decide if additional immunotherapy with sintilimab is needed. The goal is to see if this personalized approach can help prevent the cancer from coming back. About 115 adults will take part across two hospitals in China.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADJUVANT IMMUNOTHERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Guangdong Provincial People's Hospital
RECRUITINGGuangzhou, Guangdong, 510080, China
-
The third people's hospital of chengdu
RECRUITINGChengdu, Sichuan, 610031, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immune drug outsmart Hard-to-Treat tumors?
- Can a pill plus immunotherapy and targeted radiation shrink lung tumors before surgery?
- Can a targeted drug combo boost chemoradiation in EGFR-Positive lung cancer?
- Cancer drug pralsetinib may change how the body processes other medications
- Blood test may let cancer patients take safe breaks from immunotherapy
- New pill takes on tough lung cancer mutation